These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 20029798

  • 1. Sustained low-dose growth hormone therapy optimizes bioactive insulin-like growth factor-I level and may enhance CD4 T-cell number in HIV infection.
    Andersen O, Hansen BR, Troensegaard W, Flyvbjerg A, Madsbad S, Ørskov H, Nielsen JO, Iversen J, Haugaard SB.
    J Med Virol; 2010 Feb; 82(2):197-205. PubMed ID: 20029798
    [Abstract] [Full Text] [Related]

  • 2. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB, Hansen TB, Frystyk J, Ladefoged SD, Pedersen FB, Christiansen JS.
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [Abstract] [Full Text] [Related]

  • 3. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
    Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, Perno CF, Monforte Ad, Galli M, Meroni L.
    AIDS; 2006 Aug 22; 20(13):1727-36. PubMed ID: 16931937
    [Abstract] [Full Text] [Related]

  • 4. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
    Andersen O, Haugaard SB, Flyvbjerg A, Andersen UB, Ørskov H, Madsbad S, Nielsen JO, Iversen J.
    Eur J Clin Invest; 2004 Aug 22; 34(8):561-8. PubMed ID: 15305891
    [Abstract] [Full Text] [Related]

  • 5. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group.
    Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216
    [Abstract] [Full Text] [Related]

  • 6. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 7. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM, Price P, Lee S, Almeida CA, Stone SF, James I, French MA.
    HIV Med; 2004 Nov 01; 5(6):407-14. PubMed ID: 15544692
    [Abstract] [Full Text] [Related]

  • 8. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM, López M, Lozano S, González-Lahoz J, Soriano V.
    J Infect Dis; 2008 Nov 15; 198(10):1466-73. PubMed ID: 18847371
    [Abstract] [Full Text] [Related]

  • 9. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B, Swiss HIV Cohort Study.
    Arch Intern Med; 2003 May 26; 163(10):1220-6. PubMed ID: 12767960
    [Abstract] [Full Text] [Related]

  • 10. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF, Price P, French MA.
    HIV Med; 2005 Jul 26; 6(4):278-83. PubMed ID: 16011533
    [Abstract] [Full Text] [Related]

  • 11. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment.
    Gelato M, McNurlan M, Freedland E.
    Clin Ther; 2007 Nov 26; 29(11):2269-88. PubMed ID: 18158071
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment.
    Sarmati L, Andreoni C, Nicastri E, Tommasi C, Buonomini A, D'Ettorre G, Corpolongo A, Dori L, Montano M, Volpi A, Narciso P, Vullo V, Andreoni M.
    J Med Virol; 2009 Mar 26; 81(3):481-7. PubMed ID: 19152399
    [Abstract] [Full Text] [Related]

  • 13. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A, Leti W, De Santis W, Marziali M, Esposito A, Fimiani C, Luzi G, Pinti M, Cossarizza A, Aiuti F, Mezzaroma I.
    Clin Infect Dis; 2008 Jun 15; 46(12):1902-10. PubMed ID: 18462177
    [Abstract] [Full Text] [Related]

  • 14. Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial.
    Gori A, Trabattoni D, Bandera A, Saresella M, Marchetti G, Gazzola L, Biasin M, Rhodes J, McDade H, Panebianco R, Galli M, Moroni M, Ferrante P, Thomas N, Franzetti F, Bray D, Clerici M.
    Antivir Ther; 2004 Aug 15; 9(4):603-14. PubMed ID: 15456092
    [Abstract] [Full Text] [Related]

  • 15. Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy.
    Pires A, Pido-Lopez J, Moyle G, Gazzard B, Gotch F, Imami N.
    Antivir Ther; 2004 Feb 15; 9(1):67-75. PubMed ID: 15040538
    [Abstract] [Full Text] [Related]

  • 16. Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults.
    Giavoli C, Cappiello V, Corbetta S, Ronchi CL, Morpurgo PS, Ferrante E, Beck-Peccoz P, Spada A.
    Clin Endocrinol (Oxf); 2004 Jul 15; 61(1):81-7. PubMed ID: 15212648
    [Abstract] [Full Text] [Related]

  • 17. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Jul 15; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency.
    Pereira AM, van der Klaauw AA, Koppeschaar HP, Smit JW, van Thiel SW, van Doorn J, Biermasz NR, Roelfsema F, Romijn JA.
    Br J Clin Pharmacol; 2006 Apr 15; 61(4):451-5. PubMed ID: 16542206
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load.
    Arnó A, Ruiz L, Juan M, Jou A, Balagué M, Zayat MK, Marfil S, Martínez-Picado J, Martínez MA, Romeu J, Pujol-Borrell R, Lane C, Clotet B.
    J Infect Dis; 1999 Jul 15; 180(1):56-60. PubMed ID: 10353861
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, Teramoto A, Shimatsu A.
    Growth Horm IGF Res; 2008 Aug 15; 18(4):307-17. PubMed ID: 18282776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.